Imidazoles Patents (Class 514/396)
-
Patent number: 8772325Abstract: The present invention is directed to novel opioid receptor modulators of Formula (I). The invention further relates to methods for preparing such compounds, pharmaceutical compositions containing them, and their use in the treatment of disorders that may be ameliorated or treated by the modulation of opioid receptors.Type: GrantFiled: October 3, 2013Date of Patent: July 8, 2014Assignee: Janssen Pharmaceutica, N.V.Inventors: Henry J. Breslin, Chaozhong Cai, Wei He, Robert W. Kavash
-
Publication number: 20140163080Abstract: The invention provides ?-2 adrenergic receptor agonist compositions and methods for treating glaucoma and other intraocular conditions. The preferred ?-2 agonist used in the inventive compositions and methods is dexmedetomidine.Type: ApplicationFiled: February 11, 2014Publication date: June 12, 2014Applicant: GNT, LLCInventor: Gerald Horn
-
Publication number: 20140155445Abstract: Disclosed are compounds of the general formula (I): compositions comprising an effective amount of said compounds either alone or in combination with other chemotherapeutic agents, and methods useful for treating or preventing cancer and for inhibiting tumour tissue growth. These compounds attenuate the oxidative damage associated with increased heme-oxygenase activity and can reduce cell proliferation in transformed cells. In addition, the described compounds and compositions are useful as neuroprotectants and for treating or preventing neurodegenerative disorders and other diseases of the central nervous system.Type: ApplicationFiled: September 18, 2013Publication date: June 5, 2014Applicants: QUEEN'S UNIVERSITY AT KINGSTON, Osta Biotechnologies Inc., The Sir Mortimer B. Davis - Jewish General HospitalInventors: Ajay Gupta, Hyman M. Schipper, Moulay Alaoui-Jamali, Walter A. Szarek, Kanji Nakatsu, Jason Z. Vlahakis
-
Publication number: 20140155446Abstract: The presently disclosed subject matter relates to pharmaceutical compositions comprising dexmedetomidine or a pharmaceutically acceptable salt thereof wherein the composition is formulated as a liquid for parenteral administration to a subject, and wherein the composition is disposed within a sealed container as a premixture. The pharmaceutical compositions can be used, for example, in perioperative care of a patient or for sedation.Type: ApplicationFiled: February 10, 2014Publication date: June 5, 2014Applicant: HOSPIRA, INC.Inventors: Priyanka Roychowdhury, Robert A. Cedergren
-
Patent number: 8741941Abstract: An object of the present invention is to provide a medicinal composition useful for external application in the treatment of a fungal infection reaching the lower part of a thick keratin layer. Provided is an antifungal medicinal composition, comprising: (1) a film-forming agent; (2) a water-soluble plasticizer in a form of a solid or a paste at 20° C. at 1 atm; and (3) an antifungal compound represented by a general formula (1) and/or a physiologically acceptable salt thereof.Type: GrantFiled: September 22, 2011Date of Patent: June 3, 2014Assignee: Pola Pharma Inc.Inventors: Hideaki Sasagawa, Madoka Ito, Takuji Nakashima, Akira Nozawa
-
Patent number: 8741928Abstract: Provided are protected antimicrobial compounds which are useful for controlling microorganisms in aqueous or water-containing systems, such as oil or gas field fluids, at elevated temperature. The antimicrobial compounds are of the formula I: wherein R, R1, R2, X and Y are as defined herein.Type: GrantFiled: December 2, 2011Date of Patent: June 3, 2014Assignees: Dow Global Technologies LLC, ANGUS Chemical CompanyInventors: Charles E. Coburn, Michael V. Enzien, Heather R. Mcginley, David W. Moore
-
Patent number: 8735437Abstract: The present invention relates to imidazolidinecarboxamide derivatives of the general formula I, wherein R, R1, R2, X and Y are as defined herein, or pharmaceutically usable salts thereof and the use thereof as medicinal substances.Type: GrantFiled: October 2, 2009Date of Patent: May 27, 2014Assignee: SanofiInventors: Gerhard Zoller, Stefan Petry, Gunter Müller, Norbert Tennagels
-
Patent number: 8735438Abstract: A compound having selective modulating activity at the alpha 2B and/or alpha 2C adrenergic receptor subtypes is represented by the general Formula 1: wherein n=1-4; X is C or N; R1-R6 can be the same or different and are independently selected from the group consisting of H, C1-6 alkyl, OCH3, OH, F, Cl, Br, CH2OH, CH2N(R7)2, C(O)R8, CH2CN, CF3, wherein R7 is H or C1-6 alkyl; and R8 is C1-6 alkyl or aryl. The compounds of Formula 1 can be incorporated in pharmaceutical compositions and used in methods of treatment of alpha 2 receptor mediated diseases and conditions.Type: GrantFiled: December 13, 2010Date of Patent: May 27, 2014Assignee: Allergan, Inc.Inventors: Santosh C. Sinha, Todd M. Heidelbaugh, Smita Bhat, Ken Chow, Michael Garst
-
Process for the production of particles comprising active agrochemical ingredients in amorphous form
Patent number: 8735321Abstract: An object of the present invention is a process for the preparation of particles which comprise two agrochemical active ingredients in amorphous form, where a melt comprising the two molten agrochemical active ingredients is emulsified in an aqueous solution and cooled. A further object is the use of an agrochemical active ingredient for inhibiting the crystallization of another agrochemical active ingredient in a preparation process for particles which comprise the two agrochemical active ingredients in amorphous form, where a melt comprising the two molten agrochemical active ingredients is emulsified in an aqueous solution and cooled. A further object is particles which comprise two agrochemical active ingredients in amorphous form. The use in plant protection is also described.Type: GrantFiled: May 6, 2009Date of Patent: May 27, 2014Assignee: BASF SEInventors: Ulrike Troppmann, Winfried Mayer, Sebastian Koltzenburg, Rafel Israels, Andreas Bauder, Ulf Schlotterbeck -
Patent number: 8729056Abstract: The agent for the prevention and/or treatment of Hand-Foot Syndrome comprising a compound with anticholinergic activity can be provided. The agent for the prevention and/or treatment of Hand-Foot Syndrome comprising a compound with anticholinergic activity can be safely administered to the patients with Hand-Foot Syndrome, and has shown the superior preventive and/or treatment effect against Hand-Foot Syndrome.Type: GrantFiled: March 30, 2011Date of Patent: May 20, 2014Assignee: Ono Pharmaceutical Co., Ltd.Inventors: Kazuhiro Ishizaka, Tadashi Nomizu, Aya Kitao
-
Patent number: 8729114Abstract: Disclosed are Cathepsin-S reversible inhibitor compounds of the formula (I) which are useful in the treatment of autoimmune and other diseases. Also disclosed are pharmaceutical compositions containing the same, and methods of making and using the same.Type: GrantFiled: March 2, 2011Date of Patent: May 20, 2014Assignee: Boehringer Ingelheim International GmbHInventors: Michael J. Burke, Derek Cogan, Donghong Amy Gao, Alexander Heim-Riether, Eugene Richard Hickey, Matthew Russell Netherton, Philip Dean Ramsden, David Charles Thompson, Zhaoming Xiong
-
Publication number: 20140134246Abstract: Disclosed herein are pharmaceutically acceptable rapid dissolve vaginal tablet compositions comprising one or more active pharmaceutical ingredients suitable for therapy via topical action or systemic absorption, and methods of making and using such compositions.Type: ApplicationFiled: November 1, 2013Publication date: May 15, 2014Applicant: Aptalis Pharmatech, Inc.Inventors: Gopi VENKATESH, Vijaya SWAMINATHAN, Jin-Wang LAI
-
Patent number: 8716322Abstract: Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases associated with the proteasome. The peptide-based compounds include an epoxide or aziridine, and functionalization at the N-terminus. Among other therapeutic utilities, the peptide-based compounds are expected to display anti-inflammatory properties and inhibition of cell proliferation. Oral administration of these peptide-based proteasome inhibitors is possible due to their bioavailability profiles.Type: GrantFiled: November 9, 2006Date of Patent: May 6, 2014Assignee: Onyx Therapeutics, Inc.Inventors: Han-Jie Zhou, Congcong M. Sun, Kevin D. Shenk, Guy J. Laidig
-
Patent number: 8710090Abstract: An azole derivative according to the invention is represented by Formula (I), wherein each of Ra and Rb denotes a hydrogen atom, or a C1-C6 alkyl group, a C2-C6 alkenyl group or a C2-C6 alkynyl group; Ra and Rb may be substituted with Xa or Xb which is a halogen atom; each of na and nb denotes 0 or the number of Xa- or Xb-substituted hydrogen atoms among the hydrogen atoms in Ra or Rb; each Y denotes a halogen atom, a C1-C4 alkyl group, a C1-C4 haloalkyl group, a C1-C4 alkoxy group, a C1-C4 haloalkoxy group, a phenyl group, a cyano group or a nitro group; m denotes 0 to 5; and A denotes a nitrogen atom or a methyne group. As a result, an azole derivative contained as an active ingredient in an agro-horticultural agent having an excellent controlling effect on diseases can be provided.Type: GrantFiled: December 7, 2010Date of Patent: April 29, 2014Assignee: Kureha CorporationInventors: Nobuyuki Araki, Toru Yamazaki, Nobuyuki Kusano, Eiyu Imai, Hisashi Kanno, Masaru Mori, Taiji Miyake
-
Publication number: 20140107173Abstract: The invention provides ?-2 adrenergic receptor agonist compositions and methods for treating glaucoma and other intraocular conditions. The preferred ?-2 agonist used in the inventive compositions and methods is dexmedetomidine.Type: ApplicationFiled: December 18, 2013Publication date: April 17, 2014Applicant: GNT, LLCInventor: Gerald Horn
-
Publication number: 20140079791Abstract: The subject of the present invention is a transdermal preparation containing pharmaceutically active ingredient, wherein the particles of the active ingredient are coated with highly volatile silicones or a mixture thereof, and these coated particles are dispersed in a gel or cream base. The volatile silicone component is hexamethyldisiloxane and/or octamethyltrisiloxane and/or decamethylpentacyclo-siloxane. A further subject of the present invention is a method for the preparation of such pharmaceutical compositions.Type: ApplicationFiled: November 15, 2013Publication date: March 20, 2014Applicant: EGIS Pharmaceuticals Public Limited CompanyInventors: Endre Mikulásik, Patrik Fazekas
-
Publication number: 20140066483Abstract: Disclosed herein is a method of upregulating regulatory T-cells, and treating diseases that would benefit from such upregulation, by administering an alpha 2 receptor agonist.Type: ApplicationFiled: November 4, 2013Publication date: March 6, 2014Applicant: Allergan, Inc.Inventors: Daniel W. Gil, John E. Donello, Veena Viswanath, Lauren M.B. Luhrs
-
Patent number: 8658678Abstract: The combination of any two of a polyol, a polyol ether, and a low carbon organic alcohol provides a synergistic effect on the solubility of azole compounds, such as metronidazole, in aqueous fluid.Type: GrantFiled: December 8, 2010Date of Patent: February 25, 2014Assignee: Dow Pharmaceutical Sciences, Inc.Inventors: Meidong Yang, Haigang Chen
-
Patent number: 8653122Abstract: An oromucosal formulation containing as an active ingredient a substituted imidazole derivative of formula (I) where Y is —CH2— or —CO—, R1 is halogen or hydroxy, R2 is H or halogen and R3 is H or lower alkyl, or an acid addition salt of this imidazole derivative, and a process for its preparation.Type: GrantFiled: November 10, 2003Date of Patent: February 18, 2014Assignee: Santhera Pharmaceuticals (Switzerland) Ltd.Inventors: Juha-Matti Savola, Päivi Juujärvi, Jukka Ilkka
-
Patent number: 8653123Abstract: The present invention relates to method of treating retinal diseases in a subject in need of such treatment, which comprises administering a therapeutically effective amount of a composition comprising a ester pro-drugs of [3-(1-(1H-imidazol-4-yl)ethyl) -2-methylphenyl]methanol, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals.Type: GrantFiled: September 15, 2011Date of Patent: February 18, 2014Assignee: Allergan, Inc.Inventors: Mohammad I. Dibas, Daniel W. Gil, Ken Chow, Liming Wang, Michael E. Garst, John E. Donello
-
Patent number: 8653083Abstract: Compounds, compositions, kits and methods for modulating hedgehog pathway activity, and treating conditions related to abnormal or aberrant hedgehog pathway activity, are disclosed.Type: GrantFiled: August 22, 2006Date of Patent: February 18, 2014Assignee: The Johns Hopkins UniversityInventors: Philip A. Beachy, Jun O. Liu
-
Patent number: 8648106Abstract: The presently disclosed subject matter relates to pharmaceutical compositions comprising dexmedetomidine or a pharmaceutically acceptable salt thereof wherein the composition is formulated as a liquid for parenteral administration to a subject, and wherein the composition is disposed within a sealed container as a premixture. The pharmaceutical compositions can be used, for example, in perioperative care of a patient or for sedation.Type: GrantFiled: April 22, 2013Date of Patent: February 11, 2014Assignee: Hospira, Inc.Inventors: Priyanka Roychowdhury, Robert A. Cedergren
-
Publication number: 20140038974Abstract: The invention provides compositions and methods for whitening of eyes and/or reducing redness of eyes. The provided compositions and methods utilize low concentrations of selective ?-2 adrenergic receptor agonists. The compositions preferably include brimonidine, dexmedetomidine, guanfacine or fadolmidine.Type: ApplicationFiled: October 3, 2013Publication date: February 6, 2014Applicant: Eye Therapies, LLCInventor: Gerald Horn
-
Publication number: 20140037577Abstract: The present invention includes methods and compositions for the treatment and prevention of protozoal parasitic infections utilizing Diindolylmethane-related indoles. Additive and synergistic interaction of Diindolylmethane-related indoles with other known anti-parasitic and pro-apoptotic agents is believed to permit more effective therapy and prevention of protozoal parasitic infections. The methods and compositions described provide new treatment of protozoal parasitic diseases of mammals and birds including malaria, leishmaniasis, trypanosomiasis, trichomoniasis, neosporosis and coccidiosis.Type: ApplicationFiled: October 10, 2013Publication date: February 6, 2014Inventor: Michael A. Zeligs
-
Publication number: 20140030312Abstract: The invention relates to the use of an antimycotic agent and an epithelial cell or endothelial cell adhesion inhibitor for producing a combination drug for the topical treatment of Candida mycoses selected from vulvovaginal candidiasis, oropharyngeal candidiasis (oral thrush), diaper dermatitis (diaper thrush) and intertriginous (Candida) eczema.Type: ApplicationFiled: October 2, 2013Publication date: January 30, 2014Inventors: Christian Noe, Marion Noe-Letschnig
-
Patent number: 8632763Abstract: The use of copolymers obtained by free-radical polymerization of a mixture of i) 30 to 80% by weight of N-vinyllactam, ii) 10 to 50% by weight of vinyl acetate, and iii) 10 to 50% by weight of a polyether, with the proviso that the total of components i), ii) and iii) equals 100% by weight, as solubilizers for slightly water-soluble substances.Type: GrantFiled: March 21, 2012Date of Patent: January 21, 2014Assignee: BASF SEInventors: Nathalie Bouillo, Marianna Pierobon, Ralf Widmaier, Rainer Dobrawa, Kathrin Meyer-Böhm, Ronald Frans-Maria Lange
-
Patent number: 8623868Abstract: In its several embodiments, this invention discloses a pharmaceutical formulation comprising at least one antineoplastic agent or a pharmaceutically acceptable salt thereof, and at least one dissolution enhancing agent sufficient to substantially dissolve said at least one antineoplastic agent in at least one aqueous diluent, wherein said dissolution enhancing agent is urea, L-histidine, L-threonine, L-asparagine, L-serine, L-glutamine or mixtures thereof; a lyophilized powder comprising said pharmaceutical formulation, and articles of manufacture thereof.Type: GrantFiled: November 7, 2011Date of Patent: January 7, 2014Assignee: Merck Sharp & Dohme Corp.Inventors: Sydney Ugwu, Vinay Radhakrishnan, Peter M. Ihnat, Lenore C. Witchey-Lakshmanan
-
Publication number: 20140005243Abstract: The presently disclosed subject matter relates to methods of administering an effective amount of dexmedetomidine to a pediatric patient in order to reduce the incidence of neurological damage. More particularly, the presently disclosed subject matter relates to methods of providing sedation or analgesia to a pediatric patient by administering a dexmedetomidine infusion and optionally a loading dose. The dexmedetomidine can be administered before, during, or after surgery.Type: ApplicationFiled: August 9, 2013Publication date: January 2, 2014Applicant: HOSPIRA, INC.Inventors: Marcelo Garcia da Rocha, Wayne Wisemandle, Dennis Stalker, Edward Koo
-
Patent number: 8618153Abstract: This disclosure concerns novel compounds of Formula (I) or as defined in the specification and compositions comprising such novel compounds. These compounds are useful antiviral agents, especially in inhibiting the function of the NS5A protein encoded by Hepatitis C virus (HCV). Thus, the disclosure also concerns a method of treating HCV related diseases or conditions by use of these novel compounds or a composition comprising such novel compounds.Type: GrantFiled: September 12, 2012Date of Patent: December 31, 2013Assignee: Bristol-Myers Squibb CompanyInventors: John A. Bender, Makonen Belema
-
Patent number: 8618122Abstract: A compound represented by general formula (I): a salt thereof, a solvate thereof, or a prodrug thereof wherein all symbols are as defined in the specification. The compound of the present invention has antagonistic activity against CXCR4 and is therefore useful as a preventive and/or therapeutic agent for CXCR4-mediated diseases, for example, inflammatory and immune diseases (for example, rheumatoid arthritis, arthritis, systemic erythematosus, retinopathy, macular degeneration, pulmonary fibrosis, transplanted organ rejection, etc.), allergic diseases, infections (for example, human immunodeficiency virus infection, acquired immunodeficiency syndrome, etc.), psychoneurotic diseases, cerebral diseases, cardiovascular disease, metabolic diseases, cancerous diseases (for example, cancer, cancer metastasis, etc.), or an agent for regeneration therapy.Type: GrantFiled: May 15, 2007Date of Patent: December 31, 2013Assignee: Ono Pharmaceutical Co., Ltd.Inventors: Kensuke Kusumi, Masaya Kokubo, Hiroshi Ochiai, Shiro Shibayama
-
Publication number: 20130345150Abstract: An ophthalmic composition comprising a polyaphron dispersion.Type: ApplicationFiled: March 14, 2012Publication date: December 26, 2013Inventor: Fraser Steele
-
Publication number: 20130338206Abstract: A novel method and composition is disclosed for treating burn injuries on human skin by promoting healing of the damaged skin. In particular, a topical liquid drug formulation is used to treat burn injuries caused by exposure of the skin to heat (thermal burns), the sun or ultraviolet radiation (sunburn), ionizing radiation (radiation burns), chemicals (chemical burns) and electricity (electrical burns). The topical burn treatment liquid contains clotrimazole as the active pharmaceutical ingredient to promote the healing of the burn damaged skin by reducing the edema, erythema, blistering, pain and other symptoms associated with burns, as well as preventing the spread of the burn damage and promoting healing.Type: ApplicationFiled: March 13, 2013Publication date: December 19, 2013Inventors: Lee K. Roberts, William L. Hickerson, Douglas B. Learn
-
Patent number: 8609709Abstract: The present invention is directed to novel opioid receptor modulators of Formula (I). The invention further relates to methods for preparing such compounds, pharmaceutical compositions containing them, and their use in the treatment of disorders that may be ameliorated or treated by the modulation of opioid receptors.Type: GrantFiled: November 30, 2012Date of Patent: December 17, 2013Assignee: Janssen Pharmaceutica, N. V.Inventors: Henry J. Breslin, Chaozhong Cai, Wei He, Robert W. Kavash
-
Patent number: 8609710Abstract: A compound represented by the following general formula (I) or a pharmacologically acceptable salt thereof, wherein A represents a C3 to C12 cycloalkyl group which may be substituted by one to three selected from a fluoro group, a hydroxy group, a C1 to C6 alkyl group, etc; R1, R2, and R3 each independently represent a hydrogen atom, a fluoro group, or a C1 to C6 alkyl group; R4 represents a hydrogen atom or a prodrug group; and Y represents —CH2—CHR5—CH2—NHR6 (wherein R5 represents a hydrogen atom, a C1 to C6 alkyl group, or a C1 to C6 alkoxy group, and R6 represents a hydrogen atom or a prodrug group), or the like exhibits excellent TAFIa inhibitory activity and is useful as a therapeutic drug for myocardial infarction, angina pectoris, acute coronary syndrome, cerebral infarction, deep vein thrombosis, pulmonary embolism, and the like.Type: GrantFiled: July 16, 2012Date of Patent: December 17, 2013Assignee: Daiichi Sankyo Company, LimitedInventors: Tsutomu Nagata, Masahiro Inoue, Yuka Ashida, Kengo Noguchi, Makoto Ono
-
Patent number: 8609708Abstract: Disclosed are nicotine-related compounds that selectively inhibit cytochrome P-450 2A6 (CYP2A6), selectively inhibit cytochrome P-450 2A13 (CYP2A13), and/or selectively modulate a nicotinic acetylcholine receptor (nAChR). Also disclosed are pharmaceutical compositions comprising a compound of the invention, as well as methods of using the pharmaceutical compositions for treating or preventing a disease or disorder associated with nicotine-ingestion, or a disease or disorder amenable to treatment by selective modulation of nAChRs.Type: GrantFiled: August 2, 2010Date of Patent: December 17, 2013Assignee: Human BioMolecular Research InstituteInventor: John R. Cashman
-
Patent number: 8598217Abstract: The invention provides compounds of the formula (I): and salts, tautomers, solvates and N-oxides thereof; wherein Q is CH or N; X is N, N+—O? or CR3; Y is N, N+—O? or CR3a; R1 and R2 are independently selected from hydrogen and various substituents as defined in the claims; or R1 and R2 together with the atoms to which they are attached, link to form an optionally substituted carbocyclic or heterocyclic aromatic or non-aromatic ring of 4 to 7 members; R3 is selected from hydrogen and various substituents; and R3a is selected from hydrogen and various substituents as defined in the claims. Also provided are pharmaceutical compositions containing the compounds of formula (I), processes for making the compounds and the medical uses of the compounds. The compounds of formula (I) have activity as inhibitors of CDK kinases and are useful in the treatment of inter alia proliferative diseases such as cancers.Type: GrantFiled: April 30, 2010Date of Patent: December 3, 2013Assignees: Astex Therapeutics Ltd., Novartis AGInventors: Steven Howard, Paul Neil Mortenson, Steven Douglas Hiscock, Alison Jo-Anne Woolford, Andrew James Woodhead, Gianni Chessari, Marc O'Reilly, Miles Stuart Congreve, Claudio Dagostin, Young Shin Cho, Fan Yang, Christine Hiu-Tung Chen, Christopher Thomas Brain, Bharat Lagu, Yaping Wang, Sunkyu Kim, John Giraldes, Michael Joseph Luzzio, Lawrence Blas Perez
-
Patent number: 8598078Abstract: Compounds of Formula I wherein the substituents are as defined in Claim 1, and the agrochemically acceptable salts and all stereoisomers and tautomeric forms of the compounds of formula I can be used as agrochemical active ingredients and can be prepared in a manner known per se.Type: GrantFiled: August 21, 2008Date of Patent: December 3, 2013Assignee: Syngenta Crop Protection, LLCInventors: Olivier Loiseleur, Roger Graham Hall, André Denis Stoller, Gerald Wayne Craig, André Jeanguenat, Andrew Edmunds
-
Patent number: 8580833Abstract: The present invention provides imidazole derivatives of Formula (I) and pharmaceutically acceptable salts thereof. These compounds are useful in the treatment of RAGE-mediated diseases such as Alzheimer's Disease. The present invention further relates to methods for the preparation of compounds of Formula (I) and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising such compounds, and the use the such compounds and/or pharmaceutical compositions in treating RAGE-mediated diseases.Type: GrantFiled: September 23, 2010Date of Patent: November 12, 2013Assignee: TransTech Pharma, Inc.Inventors: David Jones, Raju Bore Gowda, Rongyuan Xie
-
Publication number: 20130296346Abstract: The invention relates to compounds of formula (I): or a pharmaceutically acceptable salt, prodrug or solvate thereof, a method of synthesis of said compounds, pharmaceutical compositions comprising them and their use as a medicament for treating inflammatory diseases.Type: ApplicationFiled: November 22, 2011Publication date: November 7, 2013Applicant: Faes Farma, S.A.Inventors: Rosa Rodes Solanes, Neftali Garcia Dominguez, Beatriz Lopez Ortega, Melchor Alvarez De Mon Soto, Antonio De La Hera Martinez, Ana Munoz Munoz, Francisco Ledo Gomez
-
Publication number: 20130296342Abstract: The present invention provides pharmaceutical compositions containing benzene compound(s) represented by General Formula (1) below and, particularly, LPL-activating compositions for use in hyperlipidemia therapeutic and preventive agents, anti-obesity agents, and the like: wherein R1, R2, R3 and R4 are as defined in the specification.Type: ApplicationFiled: June 28, 2013Publication date: November 7, 2013Applicant: OTSUKA PHARMACEUTICAL FACTORY, INC.Inventors: Irina NEAGU, Michael OHLMEYER, Vidyadhar M. PARADKAR, Kurt W. SAIONZ, Koushi IWATA, Takashi OKAMURA, Tadao SHIBUTANI
-
Patent number: 8575207Abstract: Disclosed herein is a method of upregulating regulatory T-cells, and treating diseases that would benefit from such upregulation, by administering an alpha 2 receptor agonist.Type: GrantFiled: August 11, 2011Date of Patent: November 5, 2013Assignee: Allergan, Inc.Inventors: Daniel W. Gil, John E. Donello, Veena Viswanath, Lauren M. B. Luhrs
-
Patent number: 8563590Abstract: Dihydroxyaryl compounds and pharmaceutically acceptable esters, their synthesis, pharmaceutical compositions containing them, and their use in the treatment of IAPP or amylin fibril diseases, and the manufacture of medicaments for such treatment.Type: GrantFiled: January 12, 2012Date of Patent: October 22, 2013Assignee: ProteoTech, Inc.Inventors: Thomas Lake, Alan D. Snow
-
Patent number: 8563586Abstract: The present invention provides novel 1,5 and 1,3,5-substituted imidazole compounds in hydrophilic or lipophilic form, which are useful as angiotensin II ATI receptor antagonists suitable for transdermal delivery. The invention also provides pharmaceutical compositions containing such compounds, processes and intermediates for preparing compounds and their use in methods of treating hypertension and cardiovascular diseases.Type: GrantFiled: May 23, 2008Date of Patent: October 22, 2013Assignee: Eldrug S.A.Inventors: John Matsoukas, Michael Maragoudakis, Dimitrios Vlaxakos
-
Patent number: 8552042Abstract: The invention relates to the use of an antimycotic agent and an epithelial cell or endothelial cell adhesion inhibitor for producing a combination drug for the topical treatment of Candida mycoses selected from vulvovaginal candidiasis, oropharyngeal candidiasis (oral thrush), diaper dermatitis (diaper thrush) and intertriginous (Candida) eczema.Type: GrantFiled: May 10, 2007Date of Patent: October 8, 2013Inventors: Christian Noe, Marion Noe
-
Patent number: 8546404Abstract: Disclosed are the ERK inhibitors of formula 1.0: and the pharmaceutically acceptable salts, esters and solvates thereof. Q is a piperidine or piperazine ring that can have a bridge or a fused ring. The piperidine ring can have a double bond in the ring. All other substitutents are as defined herein. Also disclosed are methods of treating cancer using the compounds of formula 1.0.Type: GrantFiled: June 5, 2007Date of Patent: October 1, 2013Assignee: Merck Sharp & DohmeInventors: Alan B. Cooper, Yongqi Deng, Gerald W. Shipps, Jr., Neng-Yang Shih, Hugh Y. Zhu, Robert Sun, Joseph M. Kelly, Ronald J. Doll, Yang Nan, Tong Wang, Jagdish A. Desai, James J-S Wang, Youhao Dong, Vincent S. Madison, Li Xiao, Alan W. Hruza, M. Arshad Siddiqui, Ahmed A. Samatar, Sunil Paliwal, Hon-Chung Tsui, Azim Alan Celebi, Yiji Wu, Sobhana Babu Boga, Abdul-Basit Alhassan, Xiaolei Gao, Liang Zhu, Mehul Patel
-
Publication number: 20130252930Abstract: Provided herein are inhibitors of CYP11B, CYP17, and/or CYP21 enzymes of Formula (Z), (IX), (X), (XI), (XII), (XIII), (XIV), (XV), (XVI), or (XVII). Also described herein are pharmaceutical compositions that include at least one compound described herein and the use of a compound or pharmaceutical composition described herein to treat androgen-dependent diseases, disorders and conditions.Type: ApplicationFiled: December 16, 2011Publication date: September 26, 2013Applicant: BIOMARIN PHARMACEUTICAL INC.Inventors: Daniel Chu, Bing Wang, Tao Ye
-
Publication number: 20130237576Abstract: The presently disclosed subject matter relates to pharmaceutical compositions comprising dexmedetomidine or a pharmaceutically acceptable salt thereof wherein the composition is formulated as a liquid for parenteral administration to a subject, and wherein the composition is disposed within a sealed container as a premixture. The pharmaceutical compositions can be used, for example, in perioperative care of a patient or for sedation.Type: ApplicationFiled: April 22, 2013Publication date: September 12, 2013Applicant: HOSPIRA, INC.Inventors: Priyanka Roychowdhury, Robert A. Cedergren
-
Publication number: 20130217735Abstract: Disclosed are compositions and methods of preparing compositions of active fungicidal ingredients. Also disclosed are methods of using the compositions described herein to improve fungicide penetration into the plant tissue, reduce fungicide volatility and drift, decrease water solubility of the fungicides, and introduce additional biological function to fungicides.Type: ApplicationFiled: August 12, 2011Publication date: August 22, 2013Applicants: Agri-Food and BioSciences Institute, THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ALABAMAInventors: Robin D. Rogers, Louise R. Cooke
-
Patent number: 8513295Abstract: Novel classes of viral and fungal inhibitors are disclosed. These compounds are useful in treating, preventing, and/or ameliorating viral infections such as, for example, Hepatitis C Virus, West Nile Virus, Dengue Virus, and Japanese Encephalitis Virus, and fungal infections such as, for example, candidiasis.Type: GrantFiled: September 23, 2009Date of Patent: August 20, 2013Assignees: Georgetown University, Wichita State UniversityInventors: Radhakrishnan Padmanabhan, William C. Groutas, Brent E. Korba
-
Patent number: 8513294Abstract: Disclosed are compounds of the general formula (I): compositions comprising an effective amount of said compounds either alone or in combination with other chemotherapeutic agents, and methods useful for treating or preventing cancer and for inhibiting tumor tissue growth. These compounds attenuate the oxidative damage associated with increased heme-oxygenase activity and can reduce cell proliferation in transformed cells. In addition, the described compounds and compositions are useful as neuroprotectants and for treating or preventing neurodegenerative disorders and other diseases of the central nervous system.Type: GrantFiled: January 13, 2011Date of Patent: August 20, 2013Assignees: Osta Biotechnologies, Queens University at Kingston, The Sir Mortimer B. Davis-Jewish General HospitalInventors: Ajay Gupta, Hyman M. Schipper, Moulay Alaoui-Jamali, Walter A. Szarek, Kanji Nakatsu, Jason Z. Vlahakis